Table 2.

Examples of completed clinical trials related to cancer [77]

Tested compound	Condition	Clinical Trial number	Dosage	Objective	Outcomes
I3C	Cancer	Clinical Trial-Phase 1- NCT00100958	---	To study the side effects and best dose of I3C and to see how well it works compared to a placebo in preventing cancer in healthy participants.	No study results have been posted.
I3C	Breast Cancer	Clinical Trial-Phase 1- NCT00033345	400 mg daily for 4 weeks, followed by a 4-week period of 800 mg daily	To study the effectiveness of I3C in preventing breast cancer in nonsmoking women at high risk for breast cancer.	No study results have been posted.
DIM Supplement	Breast Cancer	Clinical Trial-Phase 3- NCT02525159	75 mg for 30 days	To evaluate the effectiveness of supplementation with DIM to increase the urinary ratio of estrogen metabolites 2 hydroxyestrone:16 alpha-hydroxyestrone in premenopausal women at risk of breast cancer.	No study results have been posted.
Microencapsulated DIM (BioResponse-DIM)	Prostate Cancer	Clinical Trial-Phase 2- NCT00888654	225 mg twice daily for 14–72 days	To study how well DIM works in treating patients with stage I or stage II prostate cancer undergoing radical prostatectomy.	-A mean level of 14.2 ng/g of DIM was found in prostate tissue after treatment. -The serum levels of PSA, testosterone, and DIM pre- and post-treatment were in ng/ml 6.4 and 5.8, 301 and 388 and 0.0 and 7.5, respectively. -The levels of androgen receptor in prostate tissue (units: intensity x % cells stained) were 278 in pre-treatment and 245 and post-treatment. -Two people out of 41 enrolled, presented headache, reported as a severe adverse event.
Microencapsulated DIM (BioResponse-DIM)	Cervical Dysplasia	Clinical Trial-Phase 3- NCT00212381	2 mg/kg/day	To determine if oral DIM, is associated with the regression of cervical dysplasia in otherwise healthy women.	No study results have been posted.
Brassica vegetables	Prostate Cancer	Clinical Trial - NCT00607932	At least 2 servings (½ cup/serving) daily for 6 months	To study the side effects and how well Brassica vegetable work compared with I3C in treating patients with PSA recurrence after surgery for prostate cancer.	No study results have been posted.